2-methyl-2-(tert-butyl)tetrahydrofuran | 98955-02-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: 2-methyl-2-(tert-butyl)tetrahydrofuran
• 英文别名: 2-tert-butyl-2-methyl-tetrahydrofuran；2-(1,1-dimethyl-1-ethyl)-2-methyltetrahydrofuran；2-Tert-butyl-2-methyloxolane
• CAS: 98955-02-3
• 化学式: C₉H₁₈O
• 分子量: 142.241
• InChiKey: OFYLHQMBVCAUSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-(叔丁基)-4-戊烯-1-醇 在 sodium tetrahydroborate 、 mercury(II) diacetate 作用下， 以88%的产率得到2-methyl-2-(tert-butyl)tetrahydrofuran
  参考文献：
  名称：

  Mihailović, M. Lj; Gojković; Milosavljević, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1999, vol. 38, # 1, p. 101 - 105

  摘要：

  DOI：

文献信息

• Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
  申请人：Peters Stefan

  公开号：US20110269791A1

  公开（公告）日：2011-11-03

  The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式（I）定义的化合物，其中A、B、X、m、n和o基团的定义如权利要求1中所述，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• INHIBITORS OF C-FMS KINASE
  申请人：Illig Carl R.

  公开号：US20070249685A1

  公开（公告）日：2007-10-25

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及公式I的化合物：其中Z、X、J、R2和W在规范中规定，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，该化合物抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用公式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；以及治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经源性疼痛；以及骨质疏松症、帕吉特病和其他骨吸收介导的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎、骨关节炎、假体失效、骨溶性肉瘤、骨髓瘤和肿瘤转移至骨骼。
• Cgrp Receptor Antagonists
  申请人：Burgey Christopher S.

  公开号：US20080113966A1

  公开（公告）日：2008-05-15

  Compounds of Formula (I): and Formula (II): (where variables R 2 , R 4 , A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式(I)和式(II)的化合物(其中变量R2、R4、A、B、D、W、X、Y和Z的定义如本文所述)，可用作CGRP受体拮抗剂，用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗CGRP参与的这些疾病的用途。
• QUINAZOLINEDIONES AND THEIR USE
  申请人：Liu Dong

  公开号：US20140031358A1

  公开（公告）日：2014-01-30

  The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.

  本发明揭示了式（I）的化合物，或其药学上可接受的盐或前药，其抑制聚（ADP-核糖）聚合酶（PARP），因此可用于治疗与PARP相关的疾病，障碍和病况。本发明还揭示了包含式（I）化合物的药物组合物，以及使用这些化合物抑制PARP酶，并治疗与PARP相关的疾病，障碍和病况的方法。
• NOVEL INHIBITORS OF HEPATITIC C VIRUS
  申请人：McKinnell Robert Murray

  公开号：US20150071878A1

  公开（公告）日：2015-03-12

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

  本发明提供了式(I)的化合物：其中变量在规范中定义，或其药学上可接受的盐，这些化合物是乙型肝炎病毒复制抑制剂。本发明还提供了包含这些化合物的制药组合物，使用这些化合物治疗乙型肝炎病毒感染的方法，以及制备这些化合物的有用过程和中间体。